{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:50:14Z","timestamp":1789217414800,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.vaccine.2014.05.004","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T23:17:27Z","timestamp":1400109447000},"page":"3796-3804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice"],"prefix":"10.1016","volume":"32","author":[{"given":"Yingxia","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Linton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton W.","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan W.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8489-363X","authenticated-orcid":false,"given":"Andrea","family":"Carfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders E.","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.05.004_bib0005","series-title":"Fields virology","first-page":"2699","article-title":"Cytomegaloviruses","author":"Mocarski","year":"2007"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0010","first-page":"417","article-title":"Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease","volume":"325","author":"Britt","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.coph.2008.07.002","article-title":"Antiviral strategies to combat cytomegalovirus infections in transplant recipients","volume":"8","author":"Lischka","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0020","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1016\/j.vaccine.2012.09.056","article-title":"The next generation recombinant human cytomegalovirus vaccine candidates-Beyond gB","volume":"30","author":"Lilja","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0025","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1086\/382751","article-title":"Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine","volume":"189","author":"Schleiss","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0030","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1086\/511982","article-title":"Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection","volume":"195","author":"Schleiss","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0035","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/JVI.64.3.1079-1085.1990","article-title":"Cell surface expression of human cytomegalovirus (HCMV) gp 55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response","volume":"64","author":"Britt","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0040","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0045","doi-asserted-by":"crossref","first-page":"11881","DOI":"10.1128\/JVI.74.24.11881-11892.2000","article-title":"Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73)","volume":"74","author":"Mach","year":"2000","journal-title":"J Virol"},{"issue":"Pt 7","key":"10.1016\/j.vaccine.2014.05.004_bib0050","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1099\/0022-1317-77-7-1537","article-title":"Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response","volume":"77","author":"Urban","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0055","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/infdis\/164.5.835","article-title":"Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans","volume":"164","author":"Rasmussen","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0060","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0065","doi-asserted-by":"crossref","first-page":"e1002172","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies","volume":"7","author":"Potzsch","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0070","doi-asserted-by":"crossref","first-page":"9075","DOI":"10.1016\/j.vaccine.2011.09.056","article-title":"Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/infdis\/169.1.83","article-title":"Epitope-specific distribution of IgG subclasses against antigenic domains on glycoproteins of human cytomegalovirus","volume":"169","author":"Urban","year":"1994","journal-title":"J Infect Dis"},{"issue":"Pt 10","key":"10.1016\/j.vaccine.2014.05.004_bib0080","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1099\/0022-1317-73-10-2693","article-title":"Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product","volume":"73","author":"Kaye","year":"1992","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0085","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00018-008-7570-z","article-title":"Entry of herpesviruses into mammalian cells","volume":"65","author":"Heldwein","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/JVI.01910-07","article-title":"Characterization of the human cytomegalovirus gH\/gL\/UL128-131 complex that mediates entry into epithelial and endothelial cells","volume":"82","author":"Ryckman","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0095","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0100","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1099\/vir.0.81921-0","article-title":"Role of human cytomegalovirus UL131A in cell type-specific virus entry and release","volume":"87","author":"Adler","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0105","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1099\/vir.0.18952-0","article-title":"Two novel spliced genes in human cytomegalovirus","volume":"84","author":"Akter","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1099\/vir.0.80474-0","article-title":"Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells","volume":"86","author":"Gerna","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0115","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1128\/JVI.78.18.10023-10033.2004","article-title":"Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes","volume":"78","author":"Hahn","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0120","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0125","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/315022","article-title":"A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant","volume":"180","author":"Pass","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0130","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0135","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0140","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1086\/588385","article-title":"Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects","volume":"197","author":"Wloch","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0145","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0150","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2008.07.092","article-title":"Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection","volume":"26","author":"Cui","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0155","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.vaccine.2012.12.009","article-title":"Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies","volume":"31","author":"Loomis","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0160","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1128\/JVI.79.5.2754-2767.2005","article-title":"Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements","volume":"79","author":"Sampaio","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0165","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1099\/0022-1317-82-6-1429","article-title":"In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells","volume":"82","author":"Grazia Revello","year":"2001","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0166-3542(94)90048-5","article-title":"Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication","volume":"24","author":"Nokta","year":"1994","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0175","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1128\/JVI.67.3.1269-1277.1993","article-title":"Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5\u2032-noncoding region and the E2 envelope glycoprotein","volume":"67","author":"Kinney","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0180","doi-asserted-by":"crossref","first-page":"10394","DOI":"10.1128\/JVI.77.19.10394-10403.2003","article-title":"An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector","volume":"77","author":"Perri","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0185","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1016\/j.vaccine.2007.08.016","article-title":"Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus","volume":"25","author":"Reap","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0190","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1128\/JVI.01669-12","article-title":"A vaccine based on the Rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in Rhesus Macaques","volume":"87","author":"Wussow","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.004_bib0195","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1016\/j.vaccine.2012.10.053","article-title":"Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus","volume":"30","author":"Fu","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14006604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14006604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T12:17:24Z","timestamp":1597839444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14006604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":39,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0264410X14006604"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.05.004","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}